11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

Cameron, David, Prof ; Piccart-Gebhart, Martine J, PhD ; Gelber, Richard D, PhD ; Procter, Marion, PhD ; Goldhirsch, Aron, MD ; de Azambuja, Evandro, MD ; Castro, Gilberto, MD ; Untch, Michael, MD ; Smith, Ian, MD ; Gianni, Luca, MD ; Baselga, Jose, MD ; Al-Sakaff, Nedal, PhD ; Lauer, Sabine, PhD ; McFadden, Eleanor, MA ; Leyland-Jones, Brian, MBBS ; Bell, Richard, MBBS ; Dowsett, Mitch, PhD ; Jackisch, Christian, MD

The Lancet (British edition), 2017-03, Vol.389 (10075), p.1195-1205 [Revista revisada por pares]

England: Elsevier Ltd

Texto completo disponible